
Noritoshi Kobayashi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6788939/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms. Internal Medicine, 2023, 62, 159-167.	0.7	4
2	Development of a list of competencies and entrustable professional activities for resident physicians during death pronouncement: a modified Delphi study. BMC Medical Education, 2022, 22, 119.	2.4	4
3	Neuroendocrine tumor theranostics. Cancer Science, 2022, 113, 1930-1938.	3.9	8
4	Detection rate of endoscopic ultrasound and computed tomography in diagnosing pancreatic neuroendocrine neoplasms including small lesions: A multicenter study. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 950-959.	2.6	2
5	Safety and response after peptide receptor radionuclide therapy with ¹⁷⁷ Luâ€DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 487-499.	2.6	7
6	Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial. Cancers, 2022, 14, 2112.	3.7	11
7	Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. Cancers, 2022, 14, 3317.	3.7	2
8	Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma. Cancer Science, 2021, 112, 1936-1942.	3.9	12
9	Gut microbiota composition associated with hepatic fibrosis in nonâ€obese patients with nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2275-2284.	2.8	26
10	Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms. Internal Medicine, 2021, 60, 977-983.	0.7	3
11	Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds. Oncogenesis, 2021, 10, 33.	4.9	13
12	IgG4â€related sclerosing cholangitis may be a risk factor for cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 524-532.	2.6	7
13	Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake. Oncologist, 2021, 26, e1862-e1869.	3.7	2
14	Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 727-739.	2.6	5
15	Severe anaphylaxis caused by intravenous antiâ€cancer drugs. Cancer Medicine, 2021, 10, 7174-7183.	2.8	9
16	Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Annals of Nuclear Medicine, 2021, 35, 1332-1341.	2.2	8
17	JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. Journal of Gastroenterology, 2021, 56, 1033-1044.	5.1	58
18	FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Pancreatology, 2020, 20, 1519-1525.	1.1	6

Noritoshi Kobayashi

#	Article	IF	CITATIONS
19	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 996-1007.	8.1	22
20	Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. Pancreatology, 2020, 20, 1421-1427.	1.1	18
21	Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype. Frontiers in Oncology, 2020, 10, 555963.	2.8	1
22	Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study. Trials, 2020, 21, 453.	1.6	4
23	Retrospective analysis of Peptide Receptor Radionuclide Therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumor Journal of Clinical Oncology, 2020, 38, e16700-e16700.	1.6	0
24	Prolonged survival in a patient with multiple liver metastases from a pancreatic neuroendocrine tumor treated with Peptide Receptor Radiotherapy (PRRT). Suizo, 2020, 35, 97-103.	0.1	0
25	Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. Annals of Surgical Oncology, 2019, 26, 1385-1393.	1.5	36
26	Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility. PLoS ONE, 2019, 14, e0224921.	2.5	25
27	Impact ofUGT1A1genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoingFOLFIRINOX. Cancer Science, 2019, 110, 707-716.	3.9	22
28	Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology, 2019, 19, 127-135.	1.1	65
29	Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. Oncotarget, 2019, 10, 1775-1784.	1.8	8
30	Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Pancreas, 2018, 47, 631-636.	1.1	15
31	Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy. Cancer Chemotherapy and Pharmacology, 2018, 82, 661-668.	2.3	25
32	Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. Clinical Cancer Research, 2017, 23, 4625-4632.	7.0	150
33	Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. Medicine (United States), 2017, 96, e6769.	1.0	20
34	Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. Journal of Gastroenterology, 2017, 52, 9-18.	5.1	48
35	Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer Journal of Clinical Oncology, 2017, 35, 429-429.	1.6	1
36	Does primary site of colorectal cancer become a prognostic factor of patients undergoing curative resection of liver metastases?. Journal of Clinical Oncology, 2017, 35, 772-772.	1.6	2

Noritoshi Kobayashi

#	Article	IF	CITATIONS
37	Primary Hepatic Neuroendocrine Carcinoma. Japanese Journal of Gastroenterological Surgery, 2017, 50, 9-17.	0.1	4
38	Endoscopic inside stent placement is suitable as a bridging treatment for preoperative biliary tract cancer. BMC Gastroenterology, 2015, 15, 8.	2.0	30
39	Imaging Findings of Pancreatic Cystic Lesions in von Hippel-Lindau Disease. Internal Medicine, 2012, 51, 1301-1307.	0.7	15
40	Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreatology, 2012, 12, 141-145.	1.1	38
41	A case of multiple ulcers of the small intestine observed by capsule endoscopy and single-balloon enteroscopy. Progress of Digestive Endoscopy, 2012, 80, 116-117.	0.0	0
42	Small Intestinal Metastasis From Carcinoma of the Lung. Clinical Gastroenterology and Hepatology, 2011, 9, e103.	4.4	4
43	Complications of the treatment of endoscopic biliary strictures developing after liver transplantation. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 202-210.	2.6	16
44	Rectal carcinoma with metachronous metastasis to the extrahepatic bile duct without liver tumor. Clinical Journal of Gastroenterology, 2011, 4, 278-282.	0.8	3
45	FOXP3+ Regulatory T Cells and Tumoral Indoleamine 2,3-Dioxygenase Expression Predicts the Carcinogenesis of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Pancreatology, 2010, 10, 631-640.	1.1	22
46	Clinical classification of congenital extrahepatic portosystemic shunts. Hepatology Research, 2010, 40, 585-593.	3.4	48
47	Duodenal gastrointestinal stromal tumor resembling a pancreatic neuroendocrine tumor in a patient with neurofibromatosis type I (von Recklinghausen's disease): a case report. Journal of Medical Case Reports, 2010, 4, 302.	0.8	8
48	Characterization of K-ras gene mutations in association with mucinous hypersecretion in intraductal papillary-mucinous neoplasms. Journal of Hepato-Biliary-Pancreatic Surgery, 2008, 15, 169-177.	2.0	11
49	Prognostic Value of Tumor Architecture, Tumor-Associated Vascular Characteristics, and Expression of Angiogenic Molecules in Pancreatic Endocrine Tumors. Clinical Cancer Research, 2007, 13, 187-196.	7.0	85
50	FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis. Clinical Cancer Research, 2007, 13, 902-911.	7.0	385
51	A case of primary intestinal GIST diagnosed by double-balloon enteroscope. Progress of Digestive Endoscopy, 2007, 71, 94-95.	0.0	2
52	A case of successful resection of the islet cell tumor of the pancreas during endoscopic nasopancreatic drainage (ENPD) before the operation. Progress of Digestive Endoscopy, 2005, 66, 100-101.	0.0	0
53	Case reports: chemoradiotherapy for locally advanced neuroendocrine carcinoma of the gallbladder. Clinical Journal of Gastroenterology, 0, , .	0.8	2